Indian Formulations

Alkem Lab's, over a span of nearly four decades has developed a strong reputation of its strengths in marketing and sales which reflect the sturdy efforts and focus on brand building.

11 of Alkem Lab's brands are listed in the top 300 pharmaceutical brands in India, as per June 2011 IMS. Alkem Lab's is rated No. 1 in Cephalosporin formulations and No. 2 in the overall anti-bacterial segment. Alkem Lab's has touched most of the therapy segments including Gastroenterology, Orthopaedics, Oncology, Neuropsychiatry, Cardiovascular and Gynaecology to mention a few, and is considered as forerunners in some segments.

SBUs (Strategic Business Units)
At Alkem Lab's, our domestic business is modelled through strong and established therapy focussed Strategic Business Units (SBUs).

Our SBUs focus on respective therapies as follows:

Main (Alkem I/II)		Ulticare		Bergen		Alkem Pharma		Pentacare	Neuroscience
Anti-infective Pain Management & Gastro Division		Anti-infective & Respiratory Division		Anti-infective Bone Health Division		Extra Urban Division		Neurology	Advanced Neurology
Bergen Zurieve		Derma Care		Mediva		Cytomed		Aliva	Futura
Gynecology and Infertility		Dermatology		Cardiology & Diabetology		Oncology Division		Generic Division

While the Main SBU, Ulticare and Bergen are the torchbearers of Alkem Lab's successful run, the newer speciality SBUs, Pentacare (Neurology), Neurosciences (Neuropsychiatry), Mediva (Cardio-Diabeto), Cytomed (Oncology) and Dermacare (Dermatology) are gaining momentum and are enhancing their market share in the chronic therapy segment with a wide range of products in their respective categories.

Alkem Lab's generic business shares a substantial share of the market with its two SBUs Aliva and Futura focused exclusively on generics.

Alkem Lab's Pharma is Alkem Lab's endeavour to venture into the potential extra-urban space existing in the India pharmaceutical market.